Abstract
A conversation with David Sutton, co-director of the Staffordshire Thrombosis and Anticoagulation Centre, University Hospitals North Midlands, UK, and Sue Rhodes, venous thromboembolism (VTE) clinical nurse specialist and joint Anticoagulant Lead at Great Western Hospitals, Swindon, UK. VTE is one of the major causes of morbidity and mortality, and is still a bigger killer than breast cancer, prostate cancer, and road traffic accidents.1 While there has been little change in the number of cases since 2010, treatment options have improved. EMJ talked to thromboembolism experts about VTE extension treatment and its role in preventing recurrence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
